Editas Medicine, Inc., (formerly Gengine, Inc.), is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| EDIT | Editas Medicine, Inc. | 2026-10-15 14:20:59 | 2.42 | 0.16 | 7.06 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EDIT | 0001650664 | Editas Medicine, Inc. | US28106W1036 | 5299000AON4Q9NT2JE42 | 464097528 | Nasdaq | 2836 | Biological Products, (No Diagnostic Substances) | 1231 | DE | 11 HURLEY ST. | CAMBRIDGE | MA | 02141 | UNITED STATES | US | 617-401-9000 | 11 HURLEY ST., CAMBRIDGE, MA, 02141 | 11 HURLEY ST., CAMBRIDGE, MA, 02141 | — | Biotechnology | 2013 | Gilmore O'Neill | 226 | http://editasmedicine.com | 191,377,146 | 153,530,898 | 153,580,035 | Editas Medicine, Inc., (formerly Gengine, Inc.), is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado. | 2026-10-09 03:34:07 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 191,377,146 | -192,470,006 | -50.1424 | 97,871,999 | 14,895,715 | 17.9518 |
| 2024 | 383,847,152 | -287,280,847 | -42.8057 | 82,976,284 | 1,162,434 | 1.4208 |
| 2023 | 671,127,999 | 37,321,352 | 5.8884 | 81,813,850 | 12,843,662 | 18.622 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Amy Parison | Chief Financial Officer, Senior Vice President | 2025 | 394,202 | — | 0 | 154,048 | 7,270 | 821,655 |
| Gilmore O’Neill | Chief Executive Officer, President | 2025 | 686,574 | — | 0 | 375,164 | 8,980 | 2,353,655 |
| Linda C. Burkly | Chief Scientific Officer, Executive Vice President | 2025 | 517,169 | — | 0 | 206,993 | 10,810 | 1,176,389 |
| Erick Lucera | Chief Financial Officer, Executive Vice President | 2024 | 482,600 | — | 350,176 | 234,544 | 8,290 | 1,809,321 |
| Gilmore O’Neill | Chief Executive Officer, President | 2024 | 667,100 | — | 1,296,544 | 440,286 | 8,900 | 5,126,868 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 87 |
| 2024 | 246 |
| 2023 | 265 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 40,520,000 | 32,314,000 | 78,123,000 |
| Cost Of Revenue | — | — | — |
| Gross Profit | 40,520,000 | 32,314,000 | 78,123,000 |
| Research And Development Expenses | 89,953,000 | 199,247,000 | 177,651,000 |
| General And Administrative Expenses | 49,903,000 | 71,987,000 | 69,653,000 |
| Operating Expenses | 200,530,000 | 283,466,000 | 247,304,000 |
| Operating Income | -160,010,000 | -251,152,000 | -169,181,000 |
| Net Income | -160,060,000 | -237,093,000 | -153,219,000 |
| Earnings Per Share Basic | -1.8 | -2.88 | -2.02 |
| Earnings Per Share Diluted | -1.8 | -2.88 | -2.02 |
| Weighted Average Shares Outstanding Basic | 88,745,908 | 82,338,220 | 75,965,633 |
| Weighted Average Shares Outstanding Diluted | 88,745,908 | 82,338,220 | 75,965,633 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 146,645,000 | 131,541,000 | 123,652,000 |
| Marketable Securities Current | 0 | 138,372,000 | 199,459,000 |
| Accounts Receivable | 15,176,000 | 16,266,000 | 10,187,000 |
| Inventories | — | — | — |
| Non Trade Receivables | — | — | — |
| Other Assets Current | 2,074,000 | 3,136,000 | 7,531,000 |
| Total Assets Current | 163,895,000 | 289,315,000 | 340,829,000 |
| Marketable Securities Non Current | — | 0 | 104,024,000 |
| Property Plant And Equipment | 3,542,000 | 14,497,000 | 12,032,000 |
| Other Assets Non Current | 2,976,000 | 5,223,000 | 8,588,000 |
| Total Assets Non Current | 22,639,000 | 52,274,000 | 158,324,000 |
| Total Assets | 186,534,000 | 341,589,000 | 499,153,000 |
| Accounts Payable | 2,605,000 | 5,493,000 | 8,269,000 |
| Deferred Revenue | 0 | 6,221,000 | 8,221,000 |
| Short Term Debt | 5,000,000 | 5,000,000 | — |
| Other Liabilities Current | 32,610,000 | 45,859,000 | 34,563,000 |
| Total Liabilities Current | 46,246,000 | 77,225,000 | 63,217,000 |
| Long Term Debt | 53,605,000 | 57,434,000 | — |
| Other Liabilities Non Current | 2,815,000 | 3,072,000 | 1,800,000 |
| Total Liabilities Non Current | 113,000,000 | 130,090,000 | 86,839,000 |
| Total Liabilities | 159,246,000 | 207,315,000 | 150,056,000 |
| Common Stock | 10,000 | 8,000 | 8,000 |
| Retained Earnings | -1,628,503,000 | -1,468,443,000 | -1,231,350,000 |
| Accumulated Other Comprehensive Income | 0 | 268,000 | 198,000 |
| Total Shareholders Equity | 27,288,000 | 134,274,000 | 349,097,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 5,277,000 | 5,809,000 | 6,064,000 |
| Share Based Compensation Expense | 10,000,000 | 21,417,000 | 19,798,000 |
| Other Non Cash Income Expense | 449,000 | 415,000 | -1,596,000 |
| Change In Accounts Receivable | -1,090,000 | 6,079,000 | 5,042,000 |
| Change In Inventories | — | — | — |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | -1,040,000 | -3,366,000 | 3,335,000 |
| Change In Accounts Payable | -2,888,000 | -2,286,000 | -1,492,000 |
| Change In Other Liabilities | -13,184,000 | 1,271,000 | 1,800,000 |
| Cash From Operating Activities | -165,241,000 | -210,284,000 | -132,178,000 |
| Purchases Of Marketable Securities | 0 | 86,217,000 | 258,517,000 |
| Sales Of Marketable Securities | 139,006,000 | 257,189,000 | 259,505,000 |
| Acquisition Of Property Plant And Equipment | 607,000 | 8,826,000 | 4,719,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | 138,668,000 | 162,146,000 | -3,731,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 42,848,000 | 0 | 117,079,000 |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | — | 57,000,000 | — |
| Repayment Of Long Term Debt | 2,872,000 | — | — |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | 40,470,000 | 56,027,000 | 118,039,000 |
| Change In Cash | 13,897,000 | 7,889,000 | -17,870,000 |
| Cash At End Of Period | 146,645,000 | 131,541,000 | 123,652,000 |
| Income Taxes Paid | — | — | — |
| Interest Paid | — | — | — |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | -1.8 | -2.88 | -2.02 |
| Price To Earnings Ratio | -1.1389 | -0.441 | -5.0149 |
| Earnings Growth Rate | -37.5 | 42.5743 | -37.0717 |
| Price Earnings To Growth Ratio | 0.0304 | -0.0104 | 0.1353 |
| Book Value Per Share | 0.3075 | 1.6308 | 4.5955 |
| Price To Book Ratio | 6.667 | 0.7788 | 2.2043 |
| Ebitda | -148,612,000 | -229,156,000 | -147,155,000 |
| Enterprise Value | 93,889,111.4 | 35,462,539.4 | — |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | 2.1476 | 0.465 | — |
| Capital Expenditures | -5,678,000 | 8,274,000 | 2,527,000 |
| Free Cash Flow | -159,563,000 | -218,558,000 | -134,705,000 |
| Return On Equity | -5.8656 | -1.7657 | -0.4389 |
| One Year Beta | 2.2129 | 1.8885 | 1.7279 |
| Three Year Beta | 2.0116 | 2.0417 | 2.0348 |
| Five Year Beta | 2.0583 | 1.6091 | 1.6405 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Ory Daniel Scott | EVP, Chief Medical Officer | 2026-09-08 | 950,000 | A | 950,000 |
| O'Neill Gilmore Neil | Director, CEO | 2026-09-03 | 5,124 | D | 243,189 |
| Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | 2026-09-03 | 709 | D | 61,660 |
| Ellinor Patrick Thomas II | Director | 2026-08-06 | 103,400 | A | 103,400 |
| Parison Amy | SVP, Chief Financial Officer | 2026-08-03 | 678 | D | 14,292 |
| Name Of Reporting Person | Type Of Reporting Person | Report Date | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| James M Inhofe | Senator | 2019-12-20 | Sale (Full) | 2019-02-04 | Self | $15,001 - $50,000 |
| James M Inhofe | Senator | 2019-02-25 | Sale (Full) | 2019-02-04 | Self | $15,001 - $50,000 |
| James M Inhofe | Senator | 2017-11-08 | Purchase | 2017-10-19 | Self | $15,001 - $50,000 |
| Name Of Reporting Person | Report Date | State | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Daniel Goldman | 2023-05-19 | NY10 | Sale | 2023-04-10 | — | $1,001 - $15,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| Activest Wealth Management | 2026-09-30 | 10,280 | 4,000 | 2.57 |
| Fortitude Family Office, LLC | 2026-09-30 | 1,542 | 600 | 2.57 |
| Essential Partners LLC | 2026-09-30 | 1,465 | 570 | 2.5702 |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | 2026-09-30 | 111,450 | 39,243 | 2.84 |
| INDEPENDENT FINANCIAL GROUP, LLC | 2026-09-30 | 52,454 | 20,410 | 2.57 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| VICTORY PORTFOLIOS III | 2026-07-31 | Victory Extended Market Index Fund | USMIX | 17,642 | 45,516.36 | 0.0056 |
| INVESCO EXCHANGE-TRADED FUND TRUST | 2026-07-31 | Invesco RAFI US 1500 Small-Mid ETF | PRFZ | 119,007 | 307,038.06 | 0.0111 |
| Global X Funds | 2026-07-31 | Global X Russell 2000 ETF | RSSL | 47,823 | 123,383.34 | 0.0083 |
| Advisors' Inner Circle Fund III | 2026-07-31 | I Shares | KCXIX | 556 | 1,434.48 | 0.0004 |
| PRINCIPAL FUNDS, INC. | 2026-07-31 | R-6 | PCSMX | 7,754 | 20,005.32 | 0.0008 |